Research & Development



  隋越道︰“陛下可要降罪于此人?”   “我發現賬簿上注明,幽州的糧倉已經有存糧六十萬擔?”2013彩票中奖新闻   “永安侯昨日燒毀了雲氏醫館,還發布公告,雲氏醫館從即日起停業,開業時間不定。”2014079彩票3d杀码   志得意滿的董仲舒為這一場戰爭敲響了結束的鐘鼓。   一直保持沉默的驃騎大將軍霍去病忽然道︰“考試必須進行!”2013福利彩票双色球走势图   雲瑯又喝了一口醒酒湯苦笑道︰“可怕之處就在于你沒有,如果你做了,事情反倒簡單的多。”

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo